

HEALTHCARE CONFERENCE 2023

Day 1: Tuesday, 14 November

7:55AM	INTRODUCTION	
8:00AM	AROA BIOSURGERY (ARX)	Session 1
8:30AM	PRO MEDICUS (PME)	
9:00AM	4DMEDICAL (4DX)	
9:30AM	AVITA MEDICAL (AVH)	
10:00AM	MONASH IVF GROUP (MVF)	
10:25AM	MORNING TEA	
10:30AM	NANOSONICS (NAN)	Session 2
11:00AM	MEDICAL DEVELOPMENTS (MVP)	
12:00PM	CURVEBEAM AI (CVB)	
12:25PM	LUNCH	
1:00PM	NEUREN PHARMACEUTICALS (NEU)	Session 3
1:30PM	MESOBLAST (MSB)	
2:00PM	STARPHARMA (SPL)	
2:30PM	PARADIGM BIOPHARMACEUTICALS (PAR)	
2:55PM	AFTERNOON TEA	
3:00PM	ALCIDION (ALC)	Session 4
3:30PM	COGSTATE (CGS)	
4:00PM	ONEVIEW HEALTHCARE (ONE)	
4:25PM	AFTERNOON TEA	
4:30PM	AVECHO BIOTECHNOLOGY (AVE)	Session 5
4:45PM	DIMERIX (DXB)	
5:00PM	CYNATA THERAPEUTICS (CYP)	
5:15PM	BOTANIX PHARMACEUTICALS (BOT)	
5:25PM	WRAP-UP	

HEALTHCARE CONFERENCE 2023

Day 2: Wednesday, 15 November

8:25AM INTRODUCTION

8:30AM ACTINOGEN MEDICAL (ACW)

9:00AM SYNTARA (PXS)

9:30AM EMVISION MEDICAL DEVICES (EMV)

10:00AM NEXT SCIENCE (NXS)

10:25AM MORNING TEA

10:30AM TELIX PHARMACEUTICALS (TLX)

11:00AM RADIOPHARM THERANOSTICS (RAD)

11:30AM CLARITY PHARMACEUTICALS (CU6)

12:00PM CYCLOPHARM (CYC)

12:25PM EBR SYSTEMS (EBR)

12:50PM LUNCH

1:00PM POLYNOVO (PNV)

1:30PM MICRO-X (MX1)

2:00PM CLINUVEL PHARMACEUTICALS (CUV)

2:30PM IMMUTEP (IMM)

2:55PM AFTERNOON TEA

3:00PM IMUGENE (IMU)

3:30PM CHIMERIC THERAPEUTICS (CHM)

3:55PM AFTERNOON TEA

4:00PM ATOMO DIAGNOSTICS (AT1)

4:15PM LUMOS DIAGNOSTICS (LDX)

4:30PM UNIVERSAL BIOSENSORS (UBI)

4:55PM WRAP-UP

Session 1

Session 2

Session 3

Session 4


Session 5

HEALTHCARE CONFERENCE 2023

Day 3: Thursday, 16 November

8:25AM	INTRODUCTION	Session 1
9:00AM	TRAJAN GROUP (TRJ)	
9:30AM	VAXXAS	
10:00AM	MEDADVISOR (MDR)	
10:25AM	MORNING TEA	
10:30AM	GENETIC SIGNATURES (GSS)	Session 2
11:00AM	INOVIQ (IIQ)	
11:30AM	IMPEDIMED (IPD)	
12:00PM	MICROBA LIFE SCIENCES (MAP)	
12:25PM	ORTHOCELL (OCC)	
12:50PM	LUNCH	
1:00PM	VITURA HEALTH (VIT)	Session 3
1:30PM	AFT PHARMACEUTICALS (AFP)	
2:00PM	IMMVIRX	
2:25PM	AFTERNOON TEA	
2:30PM	MEDLOGICAL INNOVATIONS	Session 4
3:00PM	EVOLT	
3:30PM	QBIOTICS	
4:00PM	COMPUMEDICS (CMP)	
4:25PM	AFTERNOON TEA	
4:30PM	IMRICOR MEDICAL SYSTEMS (IMR)	Session 5
4:45PM	PROTEOMICS (PIQ)	
5:00PM	DOCTOR CARE ANYWHERE (DOC)	
5:15PM	WRAP-UP	

HEALTHCARE CONFERENCE 2023



BELL POTTER

Day 1: Tuesday, 14 November

8:00AM

AROA BIOSURGERY (ARX)

Aroa Biosurgery is a high growth soft tissue reconstruction company, engaged in the developing, manufacturing, and selling of medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally.

Market cap \$281.6M

8:30AM

PRO MEDICUS (PME)

Pro Medicus Limited provides a full range of medical imaging software to hospitals, imaging centres and health care groups worldwide. The company's Visage 7 suite of products are the foundation of an ultra-fast, clinically rich, and highly scalable platform that can be implemented in both public and private cloud environments.

Market cap \$8.53B

9:00AM

4DMEDICAL (4DX)

4DMedical Limited operates as a medical technology company in Australia and the US. It commercialises XV Technology, a four-dimensional lung imaging technology. The technology uses mathematic models and algorithms to convert X-ray scans into quantitative data enhancing the capacity of physicians to manage patients with respiratory and lung diseases.

Market cap \$161.1M


9:30AM

AVITA MEDICAL (AVH)

AVITA Medical is a regenerative medicine company leading the development and commercialisation of devices and autologous cellular therapies for skin restoration. Their FDA-approved RECELL System treats patients with thermal burn wounds and full-thickness skin defects and is used for re-pigmentation of stable depigmented vitiligo lesions.

Market cap \$415.2M

HEALTHCARE CONFERENCE 2023



BELL POTTER

Day 1: Tuesday, 14 November

10:00AM

MONASH IVF GROUP (MVF)

Monash IVF is a leader in the field of fertility services and is one of the leading providers of Assisted Reproductive Services (IVF) which is the most significant component of fertility care in Australia and South East Asia. Additionally, the Group is a significant provider of specialised women's imaging services.

Market cap \$510.4M

10:30AM

NANOSONICS (NAN)

Nanosonics develops, manufactures, and commercialises infection prevention products. Its first product, trophon, provides high level disinfection for ultrasound transducers. A new automated technology for reprocessing endoscopes is soon to be submitted to the FDA with the aim of addressing recognised deficiencies associated with cross-contamination in the current manual processes.

Market cap \$1.18B

11:00AM

MEDICAL DEVELOPMENTS (MVP)

Medical Developments International Limited is a global pain management and respiratory company based in Australia. Their lead product is Pentrox (The Green Whistle®), an inhaled, fast-acting pain relief product. They have a portfolio of respiratory products for sufferers of asthma and COPD.

Market cap \$69.5M


12:00PM

CURVEBEAM AI (CVB)

CurveBeam AI develops, manufactures, and sells point of care medical imaging, Computer Tomography (CT) scanners, coupled with AI SaaS-based clinical assessment solutions, to support medical practitioners in managing musculoskeletal conditions and bone health. CurveBeam AI has its corporate office, in Melbourne, and global operations headquartered in Pennsylvania, USA.

Market cap \$62.0M

HEALTHCARE CONFERENCE 2023



BELL POTTER

Day 1: Tuesday, 14 November

1:00PM

NEUREN PHARMACEUTICALS (NEU)

Neuren is pioneering therapies for serious neurological disorders with no/limited treatments. DAYBUE™, the world's first and only approved treatment for Rett syndrome, was launched this year in the US by Neuren's licensee Acadia Pharmaceuticals. Neuren's second drug, NNZ-2591, is in Phase 2 trials for Phelan-McDermid, Angelman, Pitt-Hopkins and Prader-Willi syndromes.

Market cap \$1.57B

1:30PM

MESOBLAST (MSB)

Mesoblast is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has a proprietary technology platform with a broad portfolio of late-stage product candidates for inflammatory diseases including acute graft-versus-host-disease, chronic heart failure, and chronic low back pain.

Market cap \$301.3M

2:00PM

STARPHARMA (SPL)

Starpharma is a biopharmaceutical company focused on developing and commercialising innovative products for significant global healthcare needs, including cancer. Starpharma is a world leader in dendrimer technology with a deep portfolio of high-value assets, including multiple clinical-stage DEP® oncology assets, corporate partnerships, IP, and in-market products, VIRALEZE™ and VivaGel® BV.

Market cap \$57.5M


2:30PM

PARADIGM BIOPHARMACEUTICALS (PAR)

Paradigm Biopharmaceuticals is a biotechnology company focused on repurposing Pentosan Polysulfate Sodium for the treatment of Osteoarthritis in the knee. The recently completed phase II study produced some highly encouraging results that are worthy of further clinical trials.

Market cap \$121.2M

HEALTHCARE CONFERENCE 2023



Day 1: Tuesday, 14 November

3:00PM

ALCIDION (ALC)

Alcidion is transforming healthcare with smart, intuitive technology solutions that improve the efficiency and quality of patient care in healthcare organisations. Alcidion proprietary software solutions complement existing environments by offering interoperability and real-time clinical data management, delivering clinical decision support at the point of care to directly improve patient outcomes.

Market cap \$88.9M

3:30PM

COGSTATE (CGS)

Brain health is profoundly important to quality of life and should be easier to measure. Cogstate provides technology and services for the measurement of cognition to pharmaceutical companies and physicians. Cogstate's market is growing with increased investment in central nervous system diseases following release of breakthrough therapies (e.g. Alzheimer's disease).

Market cap \$253.2M

4:00PM

ONEVIEW HEALTHCARE (ONE)

Serving hospitals and healthcare systems, academic medical centers, and pediatric hospitals worldwide, Oneview Healthcare's Care Experience Platform (CXP) provides a unified set of digital tools in a single bedside solution. Oneview's CXP connects patients, families and care teams with services, education, and information during hospital stays.

Market cap \$159.7M


4:30PM

AVECHO BIOTECHNOLOGY (AVE)

Avecho Biotechnology develops and commercialises innovative pharmaceutical products using its proprietary drug delivery system called TPM® to increase drug absorption. Avecho's lead asset is a proprietary oral cannabidiol (CBD) capsule about to commence a pivotal Phase III clinical trial for insomnia followed by TGA registration.

Market cap \$10.8M

HEALTHCARE CONFERENCE 2023



Day 1: Tuesday, 14 November

4:45PM

DIMERIX (DXB)

Dimerix is a clinical-stage biopharmaceutical company with a portfolio of drug candidates for inflammatory diseases, including kidney and respiratory diseases. Dimerix' lead clinical asset, QYTOVRA®, is in Phase 3 trials as a treatment for FSGS, a rare kidney disease with first interim analysis expected in March 2024.

Market cap \$74.6M

5:00PM

CYNATA THERAPEUTICS (CYP)

Cynata Therapeutics Limited is a clinical-stage biotechnology company, focussed on the development and commercialisation of a proprietary induced pluripotent stem cell (iPSC)-based platform technology, Cymerus™. This platform enables manufacture of an effectively limitless number of mesenchymal stem cell (MSC) doses from a single blood donation, from a single donor.

Market cap \$24.3M


5:15PM

BOTANIX PHARMACEUTICALS (BOT)

Botanix is focused on the regulatory approval and commercialisation of its lead dermatology product, Sofpironium Bromide – a drug for the treatment of primary axillary hyperhidrosis, a medical condition where excessive sweating occurs.

Market cap \$194.0M

HEALTHCARE CONFERENCE 2023



Day 2: Wednesday, 15 November

8:30AM

ACTINOGEN MEDICAL (ACW)

Actinogen Medical is developing a novel therapy that reduces the “stress hormone” cortisol in the brain, believed to contribute to Alzheimer’s disease and depression. Xanamem® has shown promise in multiple trials and is being studied in large Phase 2 trials.

Market cap \$39.9M

9:00AM

SYNTARA (PXS)

Syntara Limited (formerly Pharmaxis) is a clinical stage drug company focused on blood-related cancers with lead candidate PXS-5505 in a phase 2 multinational study targeting bone marrow cancer myelofibrosis. Syntara’s pipeline includes phase 1c/2 trials in scar prevention and modification and also slowing progression of neurodegenerative diseases like Parkinson’s.

Market cap \$21.7M

9:30AM

EMVISION MEDICAL DEVICES (EMV)

EMVision is an Australian medical device company commercialising portable, non-invasive, cost effective and safe neuroimaging products. Its vision is to help transform and improve the timely diagnosis and treatment of stroke and other time sensitive medical emergencies, at the point-of-care.

Market cap \$120.1M


10:00AM

NEXT SCIENCE (NXS)

Next Science is a medical technology company whose mission, is to focus on commercialising its proprietary unique non-toxic XBIO™ suite of products to reduce the impact of biofilm-based infections in human health. Next Science operates in two key areas including surgical site infection and advanced wound care.

Market cap \$90.4M

HEALTHCARE CONFERENCE 2023



Day 2: Wednesday, 15 November

10:30AM

TELIX PHARMACEUTICALS (TLX)

Telex is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices for oncology and rare diseases. Headquartered in Melbourne, Telex has international operations in the US, Europe (Belgium and Switzerland), and Japan.

Market cap \$2.98B

11:00AM

RADIOPHARM THERANOSTICS (RAD)

Radiopharm Theranostics Limited develops radiopharmaceutical and nuclear medicine products for diagnostic and therapeutic uses.

Market cap \$25.8M

11:30AM

CLARITY PHARMACEUTICALS (CU6)

Clarity is a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer. Clarity's Targeted Copper Theranostic platform of products offers significant supply, logistical and environmental advantages over the current generation of radiopharmaceutical products.

Market cap \$295.9M


12:00PM

CYCLOPHARM (CYC)

Cyclopharm is a global leader in diagnostic lung imaging through its core product, Technegas, now available in 65 countries. With USFDA approval received in September, CYC is on the verge of entering the world's largest healthcare market targeting revenues of an initial US\$180m with expected growth to over US\$900m p.a.

Market cap \$200.9M

HEALTHCARE CONFERENCE 2023



BELL POTTER

Day 2: Wednesday, 15 November

12:25PM

EBR SYSTEMS (EBR)

EBR Systems is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The WiSE® CRT System was developed to eliminate the need for cardiac pacing leads, historically the major source of complications and reliability issues in conventional pacing.

Market cap \$205.7M

1:00PM

POLYNOVO (PNV)

PolyNovo's NovoSorb range of products, provide superior outcomes and redefine healing by simplifying management of complex wounds and other forms of tissue loss. After treating over 30,000 patients globally, PolyNovo's now investing for growth via geographical expansion, indication expansion, innovative new products and scaling its manufacturing, people, and technology infrastructure.

Market cap \$893.9M

1:30PM

MICRO-X (MX1)

Micro-X Limited is a hi-tech company developing and commercialising a range of innovative products for global health and security markets, based on proprietary cold cathode, carbon nanotube emitter technology.

Market cap \$67.3M


2:00PM

CLINUVEL PHARMACEUTICALS (CUV)

CLINUVEL is a specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialised populations. CLINUVEL's lead therapy, SCENESSE®, is the world's first systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria.

Market cap \$763.9M

HEALTHCARE CONFERENCE 2023



Day 2: Wednesday, 15 November

2:30PM

IMMUTEP (IMM)

Immutep Limited is a clinical stage biotechnology company developing novel LAG-3 immunotherapies. They are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response to fight cancer and autoimmune diseases.

Market cap \$356.7M

3:00PM

IMUGENE (IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate solid tumours and blood cancers. Their vision is to transform and improve the treatment of cancer and the lives of patients.

Market cap \$559.0M

3:30PM

CHIMERIC THERAPEUTICS (CHM)

Chimeric Therapeutics is a clinical stage cell therapy company and an Australian leader in cell therapy for patients with cancer. Chimeric currently has an advanced and innovative portfolio that includes two assets with positive Phase 1A clinical data, four ongoing clinical trials and three novel technology platforms.

Market cap \$15.4M


4:00PM

ATOMO DIAGNOSTICS (AT1)

Atomo Diagnostics Limited is a global leader in the user-centred design of innovative, accurate and reliable rapid diagnostics. Atomo delivers simple, low cost, user-friendly diagnostics that consistently improve performance and reliability. With a proven track record of delivering equitable and affordable access to all those who need quality tests.

Market cap \$14.7M

HEALTHCARE CONFERENCE 2023



Day 2: Wednesday, 15 November

4:15PM

LUMOS DIAGNOSTICS (LDX)

Lumos is a fully integrated developer and manufacturer of connected, rapid, point-of-care tests and instruments for the diagnostics and healthcare industries. Lumos provides these to leading healthcare companies and has a strategic partnership with US-based Hologic. Lumos has two POC tests cleared for sale in the US and other markets.

Market cap \$39.5M


4:30PM

UNIVERSAL BIOSENSORS (UBI)

Universal Biosensors is world leader in electrochemical cell technology. Our patented technology has been used to deliver more than 10 billion diagnostic tests to patients worldwide. In 2020 UBI had 1 product but today UBI has 11 revenue generating products delivering millions of tests to customers around the world.

Market cap \$53.1M

HEALTHCARE CONFERENCE 2023



BELL POTTER

Day 3: Thursday, 16 November

9:00AM

TRAJAN GROUP (TRJ)

Trajan is a global developer and manufacturer of analytical and life sciences products and devices founded to enrich personal health through scientific tools and solutions, they support science that benefits people. Trajan has a portfolio and pipeline of new technologies which support moving towards decentralised personalised data-based healthcare.

Market cap \$202.4M

9:30AM

VAXXAS

Vaxxas is a privately held, Australian biotechnology company focused on enhancing the performance of existing and next-generation vaccines with its high-density microarray skin patch (HD-MAP). The company recently opened a custom-built biomedical facility to enable scale-up of its manufacturing capabilities and is initial targeting applications in infectious diseases and oncology.

10:00AM

MEDADVISOR (MDR)

MedAdvisor Solutions is a global leader of pharmacy-driven patient engagement solutions that provide individualised patient experiences to simplify the patient medication journey. Their solutions provide an empathetic approach, data-driven insights and innovative, patient-centric digital offerings that empower the pharmacy of the future and inspire lasting behavior change.

Market cap \$109.4M


10:30AM

GENETIC SIGNATURES (GSS)

Genetic Signatures is a global manufacturer of molecular diagnostic solutions for infectious diseases. The Company's unique syndromic testing portfolio is underpinned by patented 3base® technology. GSS recently submitted their first 510k submission to the US FDA which, upon clearance, opens the world's biggest diagnostic market.

Market cap \$80.0M

HEALTHCARE CONFERENCE 2023



Day 3: Thursday, 16 November

11:00AM

INOVIQ (IIQ)

INOVIQ is developing next-generation exosome solutions and precision diagnostics to improve the diagnosis and treatment of cancer. It has commercialised the EXO-NET pan-exosome capture tool and hTERT test for bladder cancer. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian and breast cancers.

Market cap \$53.8M

11:30AM

IMPEDIMED (IPD)

ImpediMed is a medtech company that uses bioimpedance spectroscopy to generate powerful data, maximising patient health through its SOZO® Digital Health Platform. In March 2023, the NCCN Guidelines® for Survivorship were updated to reference BIS as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema.

Market cap \$242.7M

12:00PM

MICROBA LIFE SCIENCES (MAP)

Microba Life Sciences Limited operates as a gut microbiome analysis company in Australia. It offers Insight, a test for the metagenomic analysis of the gut microbiome; and bespoke health management solutions for partners and practitioners to improve patient care.

Market cap \$92.3M


12:25PM

ORTHOCELL (OCC)

Orthocell Limited is a regenerative medicine company who develops and commercialises cell therapies and biological medical devices for the repair and regeneration of human tendon, bone, nerve, and cartilage defects in Australia and internationally.

Market cap \$75.6M

HEALTHCARE CONFERENCE 2023



Day 3: Thursday, 16 November

1:00PM

VITURA HEALTH (VIT)

Vitura Health operates its market-leading “CanView” online marketplace. The Company’s business model facilitates the exchange of information, products and services between suppliers, prescribers, pharmacies and patients, and generates tangible “network effects” providing the Company with a moat around its business model, competitive advantages, and barriers to entry.

Market cap \$207.3M

1:30PM

AFT PHARMACEUTICALS (AFP)

AFT Pharmaceuticals has a strong sales base in Australasia with expanding global sales for its R&D drugs now selling in 62 countries across the globe. This year it achieved its first US FDA approval and is now pursuing a second approval with plans to achieve two US launches in 2024.

Market cap \$335.6M

2:00PM

IMMVIRX


ImmVirX is developing novel oncolytic viruses to create powerful new cancer immunotherapy combinations. Our first virus, IVX037, is in clinical studies in late-stage cancer patients with further agents in pre-clinical development. Our novel immunotherapy harnesses the power of viruses to preferentially infect and kill cancer cells and induce strong anti-tumour immune responses.

2:30PM

MEDLOGICAL INNOVATIONS

Medlogical Innovations is a medical device company committed to the development of a breakthrough focal therapy for prostate cancer. Its patented ProFocal® System ablates prostate tissue using cooled laser energy. In place of traditional whole-gland treatments, ProFocal® accurately targets specific areas, delivering a highly precise treatment with minimal side effects.

HEALTHCARE CONFERENCE 2023



Day 3: Thursday, 16 November

3:00PM

EVOLT

Evolt develops body composition technology to promote health and wellness. The company's primary product Evolt 360 Body Composition Analyser uses the monitoring of electrical currents passed through the body to provide an in-depth body composition measurement.

3:30PM

QBIOTICS

QBiotics has more than a 20 year track record in applying a scientifically-based, data-driven approach to the discovery of novel, plant-derived small molecule scaffolds for applications in human and animal health using their proprietary discovery platform EcoLogic™.

4:00PM

COMPUMEDICS (CMP)

Compumedics Limited is a medical technology company that develops, manufactures, and commercialises innovative diagnostics technology for sleep, brain, and ultrasonic blood flow monitoring applications. Compumedics is based in Australia and has broad international reach through its own offices in the USA, France, Germany and South Korea, and distributor networks elsewhere.

Market cap \$33.7M

4:30PM

IMRICOR MEDICAL SYSTEMS (IMR)

Imricor is the only company in the world that manufactures commercial MRI-compatible medical devices, allowing cardiac catheter ablations to be performed under real-time MRI guidance.

Market cap \$98.8M

HEALTHCARE CONFERENCE 2023

Day 3: Thursday, 16 November

4:45PM

PROTEOMICS (PIQ)

Proteomics International Laboratories is a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the industrial scale study of the structure and function of proteins. Proteomics International's vision is to create a world where disease is detected early and cured simply.

Market cap \$106.4M

5:00PM

DOCTOR CARE ANYWHERE (DOC)

Doctor Care Anywhere is one of the UK's largest private providers of telehealth services, offering online GP and ANP appointments, 24/7, 365 days a year, via video and phone. They work with insurers, healthcare providers and corporate customers to connect patients to a range of digitally-enabled services on our platform.

Market cap \$18.7M

Get in touch with your Bell Potter contact for conference access or call 1300 023 557.

Information relayed as part of the Conference is to be considered general investment advice only and does not constitute advice to any person. Although we believe that the advice and information which would be covered and/or provided as part of the Conference is reliable, Bell Potter Securities Limited has not independently verified information which is derived from publicly available sources, directors and management. As such, Bell Potter Securities Limited, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information that would be presented as part of the Conference is complete or accurate. Should you wish to consider and implement said information/advice, please assess the appropriateness of this information/advice with regard to your objectives, financial situation and needs, because the advice has not taken these factors into account. Bell Potter Securities Limited does not accept any responsibility to inform you of any matter that subsequently comes to its notice, which may affect any of the information presented to you as part of the Conference. Although we are elated to host you for another, please note that you are not under any obligation to attend the Conference.